Stifel raised its price target for Esperion Therapeutics (NASDAQ:ESPR) to $45 from $30. The stock closed at $29.33 on March 2.Read More
William Blair raised its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $12 from $9 after the company licensed exclusive worldwide rights to two preclinical cardiovascular programs to Amgen (NASDAQ:AMGN).
Under the accord, Arrowhead would receive an up-front fee of $35-million and $21.5-million in equity, and up to $617-million in options and milestones, plus royalties.Read More
Maxim Group downgraded Radius Health (NASDAQ:RDUS) to “sell” from “hold” with a $24 price target. The stock closed at $50.55 on Thursday.
“At the current valuation, we believe that Radius is back to an overvalued state,” writes analyst Jason McCarthy.Read More